POMDOCTOR Ltd (POM) Stock Score, Valuation & Financial Research
POMDOCTOR Ltd is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for POM
POMDOCTOR Ltd currently has a Wall Street Score of 21/100. The stored market price is $0.73. Its financial score is 14/100. Its valuation score is 0/100. The latest WSS change is -2.9 points. These figures are a research snapshot, not a buy or sell recommendation.
What POMDOCTOR Ltd does
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
POM financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $0.73
- Market capitalization:
- $4.9M
- Revenue:
- $59.1M
- Net income:
- $-31.4M
- Free cash flow:
- $-22.1M
- Cash:
- $1.4M
- Total debt:
- $67.3M
- EPS:
- -4.64
- Financial score:
- 14/100
- Valuation score:
- 0/100
- Revenue score:
- 47/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-22.1M, showing cash burn in the current stored period.
- The balance sheet shows $1.4M of cash versus $67.3M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -2.9 points: POM decreased 2.9 points because Debt declined by 28.7 points, Buffett declined by 7.2 points.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 14/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-05.
How to research POM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.